BURLINGAME, Calif.--(BUSINESS WIRE)--Urigen Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development of treatments for urological disorders, announced today the next step in its successful merger with Valentis, Inc. The name of the Company will change to Urigen Pharmaceuticals, Inc. and will trade on the OTC Bulletin Board under the ticker symbol URGP, effective at the beginning of trading today. “The name Urigen Pharmaceuticals accurately describes our mission to develop ethical drug treatments for targeted urological disorders,” commented Bill Garner, President and CEO of Urigen Pharmaceuticals, Inc. “We believe this name change is an important and necessary next step in moving forward as a publicly traded company. We look forward to further shareholder communication”
